Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, May 30 2019

Full Issue

Durbin Does 'Not Have Confidence' New FDA Head Will Satisfactorily Address Teen Vaping Epidemic

Former Commissioner Scott Gottlieb had deemed the issue a public health epidemic, but Sen. Dick Durbin (D-Ill.) accused acting chief Ned Sharpless of not taking it as seriously.

Politico: Durbin Alarmed That New FDA Chief May 'Disappoint' On E-Cigs

Sen. Dick Durbin (D-Ill.) charged in an unusually sharp attack Wednesday that acting FDA Commissioner Ned Sharpless seemed to have "no intention" of addressing youth e-cigarette use, which his predecessor deemed a public health epidemic. His May 14 meeting with Sharpless was "one of the most alarming and disappointing meetings in my time in public service," the No. 2 Senate Democrat wrote in a letter to Sharpless, a longtime cancer researcher who took the top FDA post in April as Scott Gottlieb left. (Owermohle, 5/29)

The Hill: Durbin Urges Acting FDA Chief To Crack Down On E-Cigarettes

“It is my belief that any person leading the FDA … must, first and foremost, feel a deep sense of responsibility to protect the health and well-being of all Americans, especially our nation’s children. Unfortunately, based on our meeting, I do not have confidence that you are that leader,” Durbin said. Durbin urged Sharpless not to appeal a federal judge’s ruling earlier this month that would require the agency to speed up its review of thousands of e-cigarettes on the market “We know that kids are attracted to these products because of the kid-friendly flavors that your agency is currently, and inexplicably, refusing to regulate,” Durbin wrote. “You have the explicit authority to end FDA’s senseless decision to suspend public health review of e-cigarettes and cigars and take action today.” (Weixel, 5/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF